These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

484 related articles for article (PubMed ID: 29392440)

  • 61. Cannabis and cannabinoids: pharmacology and rationale for clinical use.
    Pertwee RG
    Forsch Komplementarmed; 1999 Oct; 6 Suppl 3():12-5. PubMed ID: 10575283
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Endocannabinoids as Guardians of Metastasis.
    Tegeder I
    Int J Mol Sci; 2016 Feb; 17(2):230. PubMed ID: 26875980
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Therapeutic Potential of Cannabinoids in Psychosis.
    Leweke FM; Mueller JK; Lange B; Rohleder C
    Biol Psychiatry; 2016 Apr; 79(7):604-12. PubMed ID: 26852073
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Cannabinoids, cannabinoid receptors and tinnitus.
    Smith PF; Zheng Y
    Hear Res; 2016 Feb; 332():210-216. PubMed ID: 26433054
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Cannabinoid-induced autophagy: Protective or death role?
    Costa L; Amaral C; Teixeira N; Correia-da-Silva G; Fonseca BM
    Prostaglandins Other Lipid Mediat; 2016 Jan; 122():54-63. PubMed ID: 26732541
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Neuronal and glial alterations in the cerebellar cortex of maternally deprived rats: gender differences and modulatory effects of two inhibitors of endocannabinoid inactivation.
    López-Gallardo M; Llorente R; Llorente-Berzal A; Marco EM; Prada C; Di Marzo V; Viveros MP
    Dev Neurobiol; 2008 Oct; 68(12):1429-40. PubMed ID: 18726913
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Glial mechanisms underlying substance use disorders.
    Linker KE; Cross SJ; Leslie FM
    Eur J Neurosci; 2019 Aug; 50(3):2574-2589. PubMed ID: 30240518
    [TBL] [Abstract][Full Text] [Related]  

  • 68. The neurobiology and evolution of cannabinoid signalling.
    Elphick MR; Egertová M
    Philos Trans R Soc Lond B Biol Sci; 2001 Mar; 356(1407):381-408. PubMed ID: 11316486
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Cannabinoids: potential targets for bladder dysfunction.
    Ruggieri MR
    Handb Exp Pharmacol; 2011; (202):425-51. PubMed ID: 21290238
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Cannabinoid receptors and their ligands.
    Pertwee RG; Ross RA
    Prostaglandins Leukot Essent Fatty Acids; 2002; 66(2-3):101-21. PubMed ID: 12052030
    [TBL] [Abstract][Full Text] [Related]  

  • 71. The endocannabinoid system of the skin. A potential approach for the treatment of skin disorders.
    Río CD; Millán E; García V; Appendino G; DeMesa J; Muñoz E
    Biochem Pharmacol; 2018 Nov; 157():122-133. PubMed ID: 30138623
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Cannabinoid receptors: where they are and what they do.
    Mackie K
    J Neuroendocrinol; 2008 May; 20 Suppl 1():10-4. PubMed ID: 18426493
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Cannabinoid receptors in brain: pharmacogenetics, neuropharmacology, neurotoxicology, and potential therapeutic applications.
    Onaivi ES
    Int Rev Neurobiol; 2009; 88():335-69. PubMed ID: 19897083
    [TBL] [Abstract][Full Text] [Related]  

  • 74. The endogenous cardiac cannabinoid system: a new protective mechanism against myocardial ischemia.
    Lamontagne D; Lépicier P; Lagneux C; Bouchard JF
    Arch Mal Coeur Vaiss; 2006 Mar; 99(3):242-6. PubMed ID: 16618028
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Endocannabinoid system: potential novel targets for treatment of schizophrenia.
    Saito A; Ballinger MD; Pletnikov MV; Wong DF; Kamiya A
    Neurobiol Dis; 2013 May; 53():10-7. PubMed ID: 23220619
    [TBL] [Abstract][Full Text] [Related]  

  • 76. New insights on endocannabinoid transmission in psychomotor disorders.
    Giuffrida A; Seillier A
    Prog Neuropsychopharmacol Biol Psychiatry; 2012 Jul; 38(1):51-8. PubMed ID: 22521335
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Role of the Endocannabinoid System in the Pathophysiology of Schizophrenia: Implications for Pharmacological Intervention.
    Leweke FM; Mueller JK; Lange B; Fritze S; Topor CE; Koethe D; Rohleder C
    CNS Drugs; 2018 Jul; 32(7):605-619. PubMed ID: 30022465
    [TBL] [Abstract][Full Text] [Related]  

  • 78. [Functional role of the endocannabinoid system in emotional homeostasis].
    Marco EM; Viveros MP
    Rev Neurol; 2009 Jan 1-15; 48(1):20-6. PubMed ID: 19145562
    [TBL] [Abstract][Full Text] [Related]  

  • 79. The role of the endocannabinoid system in the pathophysiology and treatment of irritable bowel syndrome.
    Storr MA; Yüce B; Andrews CN; Sharkey KA
    Neurogastroenterol Motil; 2008 Aug; 20(8):857-68. PubMed ID: 18710476
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Cannabinoids: Medical implications.
    Schrot RJ; Hubbard JR
    Ann Med; 2016; 48(3):128-41. PubMed ID: 26912385
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.